Irrational Opioid Crisis Volatility Nipping at AcelRx Pharmaceuticals Inc (ACRX) Presents Stellar Entry Point: H.C. Wainwright
Julie Lamb, Editor-August 7, 2017, 5:45 AM EDT
SHARE ON:
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the EU to treat moderate-to-severe acute pain in a hospital setting, had initially sent the stock on a close to 14% dive.
However, shares were rising almost 5% on Friday, and H.C. Wainwright Ed Arce sizes up this “unusually high” volatility throughout the past three weeks as ideal for a bullish AcelRx investor, for the “Irrational market provides excellent entry point, in our view.”
As such, the analyst reiterates a Buy rating on ACRX with a $7 price target, which represents a 141% increase from where the shares last closed. (To watch Arce’s track record, click here.)
Initially, shares had been surging ahead of the positive Zalviso trial amid lofty anticipation. Volatility hinges upon wary market sentiment circling the “opioid crisis” that some believe could prevent the FDA from giving the drug the green light due to drug accountability apprehensions. However, with the device error rate outperforming expectation, Arce anticipates better patient training as well as nurse inspection protocols will satisfy the FDA’s unease.
On the heels of the Phase III data read-out, Arce underscores, “[…] we believe many of the same momentum players that drove the share price up then liquidated their positions, taking their profits and driving the shares back down to close yesterday at $2.78 (-28.7% vs. NBI -1.4%). From our perspective, the current market’s myopic view of the investment opportunity in ACRX stands in stark contrast to the growing fundamental value of the shares (even under conservative commercial projections), especially given several near-term value-inflection milestones. Critically, we believe ACRX continues to trade substantially undervalued due to a misplaced association, attributed by many investors, to the ‘opioid crisis’ in the U.S. We believe this unfair taint on the company significantly discounts the shares as it ignores the core profile of both Dsuvia and Zalviso as acute, short-term analgesics provided only in medically-supervised settings (and with Dsuvia, administered only by a healthcare professional.”
TipRanks analytics demonstrate ACRX as a Buy. Out of 5 analysts polled by TipRanks in the last 3 months, 3 are bullish on AcelRX stock while 2 remain sidelined. With a return potential of 154%, the stock’s consensus target price stands at $7.38.
https://www.smarteranalyst.com/2017/08/07/irrational-opioid-crisis-volatility-nipping-acelrx-pharmaceuticals-inc-acrx-presents-stellar-entry-point-h-c-wainwright/
Recent TLPH News
- Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 • PR Newswire (US) • 05/02/2024 08:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:11:29 PM
- Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:55:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:54:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:53:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:13 PM
- Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members • PR Newswire (US) • 03/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:06:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:01:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:58:02 AM
- Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 • PR Newswire (US) • 02/26/2024 09:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:58:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2024 05:15:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:44:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:42:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:40:32 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:00:48 AM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 02/13/2024 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/06/2024 09:44:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 11:03:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:22:41 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:21:06 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM